High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. High-dose lisinopril for patients with Class II - IV New York Heart Association (NYHA) heart failure and a left ventricular ejection fraction (LVEF) of less than or equal to 30% produces better clinical results than low-dose lisinopril, and does not result in higher costs.